Biogen has entered into a license and collaboration agreement with Alectos Therapeutics to develop and commercialise AL01811 for the treatment of Parkinson’s Disease (PD).

AL01811 is a new preclinical selective GBA2 inhibitor, which has first-in-class potential to be an oral disease modifying treatment for PD patients.

The deal will combine Alectos’ small-molecule therapeutics expertise with Biogen’s development expertise in movement disorders.

Under the deal, Alectos will receive a $15m upfront payment and is eligible for potential development payments of up to $77.5m and commercial milestone payments of $630m.

Additionally, Alectos will receive tiered royalties in the high-single-digits to mid-teens.

Alectos Therapeutics president and CEO Ernest McEachern said: “By combining Alectos’ expertise in small-molecule therapeutics with Biogen’s global development expertise in Parkinson’s disease, we believe we will be well-positioned to help bring AL01811 to patients in need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We’re also energised by the opportunity to tap into Biogen’s commercial acumen in order to advance the standard of care in Parkinson’s disease and movement disorders more broadly.”

Both the companies will also work on preclinical activities for AL01811.

Meanwhile, Biogen will be responsible for the development, regulatory, manufacturing, and commercial activities as well as costs of AL01811 after it is advanced to the clinic.

Biogen R&D interim head Priya Singhal said: “Through this collaboration with Alectos, we hope to improve the lives of people living with Parkinson’s disease by advancing the research and development of a potential-first-in-class oral treatment that may slow disease progression.

“At Biogen, we aim to advance therapies that serve people with movement disorders, enabling them to have greater independence and quality of life.”